 |
The Journal of Neuroscience, November 16, 2005, 25(46):10682-10688; doi:10.1523/JNEUROSCI.1166-05.2005
Previous Article | Next Article 
Behavioral/Systems/Cognitive
Evidence for a Significant Role of 3-Containing GABAA Receptors in Mediating the Anxiolytic Effects of Benzodiazepines
Rebecca Dias,
Wayne F. A. Sheppard,
Rosa L. Fradley,
Elizabeth M. Garrett,
Joanna L. Stanley,
Spencer J. Tye,
Simon Goodacre,
Rachael J. Lincoln,
Susan M. Cook,
Rachel Conley,
David Hallett,
Alexander C. Humphries,
Sally A. Thompson,
Keith A. Wafford,
Leslie J. Street,
J. Luis Castro,
Paul J. Whiting,
Thomas W. Rosahl,
John R. Atack,
Ruth M. McKernan,
Gerard R. Dawson, and
David S. Reynolds
The Neuroscience Research Centre, Merck Sharp and Dohme Research Laboratories, Terlings Park, Harlow, Essex CM20 2QR, United Kingdom
The GABAA receptor subtypes responsible for the anxiolytic effects of nonselective benzodiazepines (BZs) such as chlordiazepoxide (CDP) and diazepam remain controversial. Hence, molecular genetic data suggest that 2-rather than 3-containing GABAA receptors are responsible for the anxiolytic effects of diazepam, whereas the anxiogenic effects of an 3-selective inverse agonist suggest that an agonist selective for this subtype should be anxiolytic. We have extended this latter pharmacological approach to identify a compound, 4,2'-difluoro-5'-[8-fluoro-7-(1-hydroxy-1-methylethyl)imidazo[1,2-á]pyridin-3-yl]biphenyl-2-carbonitrile (TP003), that is an 3 subtype selective agonist that produced a robust anxiolytic-like effect in both rodent and non-human primate behavioral models of anxiety. Moreover, in mice containing a point mutation that renders 2-containing receptors BZ insensitive ( 2H101R mice), TP003 as well as the nonselective agonist CDP retained efficacy in a stress-induced hyperthermia model. Together, these data show that potentiation of 3-containing GABAA receptors is sufficient to produce the anxiolytic effects of BZs and that 2 potentiation may not be necessary.
Key words: GABAA; benzodiazepine; anxiety; 3 subunit; agonist; stress-induced hyperthermia
Received March 24, 2005;
revised October 3, 2005;
accepted October 4, 2005.
This article has been cited by other articles:

|
 |

|
 |
 
N. R. Mirza, J. S. Larsen, C. Mathiasen, T. A. Jacobsen, G. Munro, H. K. Erichsen, A. N. Nielsen, K. B. Troelsen, E. O. Nielsen, and P. K. Ahring
NS11394 [3'-[5-(1-Hydroxy-1-methyl-ethyl)-benzoimidazol-1-yl]-biphenyl-2-carbonitrile], a Unique Subtype-Selective GABAA Receptor Positive Allosteric Modulator: In Vitro Actions, Pharmacokinetic Properties and in Vivo Anxiolytic Efficacy
J. Pharmacol. Exp. Ther.,
December 1, 2008;
327(3):
954 - 968.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Matsuoka, K. Harada, Y. Endo, A. Warashina, Y. Doi, J. Nakamura, and M. Inoue
Molecular mechanisms supporting a paracrine role of GABA in rat adrenal medullary cells
J. Physiol.,
October 15, 2008;
586(20):
4825 - 4842.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. W. Olsen and W. Sieghart
International Union of Pharmacology. LXX. Subtypes of {gamma}-Aminobutyric AcidA Receptors: Classification on the Basis of Subunit Composition, Pharmacology, and Function. Update
Pharmacol. Rev.,
September 1, 2008;
60(3):
243 - 260.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. R. Peden, C. M. Petitjean, M. B. Herd, M. S. Durakoglugil, T. W. Rosahl, K. Wafford, G. E. Homanics, D. Belelli, J.-M. Fritschy, and J. J. Lambert
Developmental maturation of synaptic and extrasynaptic GABAA receptors in mouse thalamic ventrobasal neurones
J. Physiol.,
February 15, 2008;
586(4):
965 - 987.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S.L. de Haas, S.J. de Visser, J.P. van der Post, R.C. Schoemaker, K. van Dyck, M.G. Murphy, M. de Smet, L.K. Vessey, R. Ramakrishnan, L. Xue, et al.
Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABAA {alpha}2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers
J Psychopharmacol,
January 1, 2008;
22(1):
24 - 32.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
A. B. Ali
Presynaptic Inhibition of GABAA Receptor-Mediated Unitary IPSPs by Cannabinoid Receptors at Synapses Between CCK-Positive Interneurons in Rat Hippocampus
J Neurophysiol,
August 1, 2007;
98(2):
861 - 869.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. L. Fradley, M. R. Guscott, S. Bull, D. J. Hallett, S. C. Goodacre, K. A. Wafford, E. M. Garrett, R. J. Newman, G. F. O'Meara, P. J. Whiting, et al.
Differential contribution of GABAA receptor subtypes to the anticonvulsant efficacy of benzodiazepine site ligands
J Psychopharmacol,
June 1, 2007;
21(4):
384 - 391.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
S.L. de Haas, S.J. de Visser, J.P. van der Post, M. de Smet, R.C. Schoemaker, B. Rijnbeek, A.F. Cohen, J.M. Vega, N.G.B. Agrawal, T.V. Goel, et al.
Pharmacodynamic and pharmacokinetic effects of TPA023, a GABAA {alpha}2,3 subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers
J Psychopharmacol,
June 1, 2007;
21(4):
374 - 383.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Popik, E. Kostakis, M. Krawczyk, G. Nowak, B. Szewczyk, P. Krieter, Z. Chen, S. J. Russek, T. T. Gibbs, D. H. Farb, et al.
The Anxioselective Agent 7-(2-Chloropyridin-4-yl)pyrazolo-[1,5-a]-pyrimidin-3-yl](pyridin-2-yl)methanone (DOV 51892) Is More Efficacious Than Diazepam at Enhancing GABA-Gated Currents at {alpha}1 Subunit-Containing GABAA Receptors
J. Pharmacol. Exp. Ther.,
December 1, 2006;
319(3):
1244 - 1252.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|